Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study

Abstract

Check the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown. • Check the questions that may have arisen during copy editing and insert your answers/ corrections. • Check that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the Edited manuscript. • The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct. • Please do not make changes that involve only matters of style. We have generally introduced forms that follow the journal's style. Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof. • If we do not receive your corrections within 48 hours, we will send you a reminder. • Your article will be published Online First approximately one week after receipt of your corrected proofs. This is the official first publication citable with the DOI. Further changes are, therefore, not possible. • The printed version will follow in a forthcoming issue.

Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing–remitting multiple sclerosis in Austria

“…Several studies so far demonstrated that patients may stay stable after switching (for various reasons) from IFNbeta and GLAT to DMF and TERI [23][24][25][26][27][28]. In particular, Buron et al provided data from the Danish Multiple Sclerosis Registry showing that switching from injectables to DMF and TERI in clinically stable RRMS patients did not increase the risk of disability accumulation [27].…”

“…Most clinicians wish to resort to an evidence-based decision in the case of treatment switches. However, studies comparing the clinical effectiveness between a horizontal and vertical switch after a platform therapy [interferon beta (IFN-beta) or glatiramer-acetate (GLAT)] [16] provided conflicting results [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34]. These discrepancies ask for further investigations, especially based on real-life data.…”

Dimethyl Fumarate or Teriflunomide for Relapsing–Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing Studies

“…Studies were conducted in the following countries: France (3 articles) [20,26,30]; United States (3 articles) [18,28,31]; Italy (2 articles) [21,29]; Austria [23]; Denmark [22]; Germany [19]; Iran [27]; Sweden [24]; international registry [25].…”

“…To deal with the lack of randomization, adjusted estimates were based on propensity score matching in six studies [19,24,25,[27][28][29]; multivariable regression in four studies [18,20,21,30]; inverse probability treatment weighting in three studies [22,23,26]; no correction in one studies without relevant betweenarm difference at baseline [31]. Six studies were funded by the manufacturer of DMF [18, 19,28] and TRF [24,30,31].…”

Relationship between Patient Preferences, Attitudes to Treatment, Adherence, and Quality of Life in New Users of Teriflunomide

“…Importantly, all published studies have found that oral DMTs are preferred over injectables [ 13 ]; better compliance and persistence have been reported in patients who were initially indicated for oral DMTs compared with injectables [ 14 , 15 ]. Teriflunomide is a once-daily oral DMT prescribed either as a first-line or as an alternative for patients with “needle fatigue” [ 16 ]. Of the oral DMTs, teriflunomide is likely to have a better persistence and adherence than dimethyl fumarate [ 14 , 15 ].…”